DIAGNOSTIC_TEST
Thermal imaging
Use of thermal imaging camera to capture images of peripheral vasculature (hands).
Status
Completed
Phase
Not applicable
Enrollment
66
Locations
1
Results
Not posted
Publications
0
Study summary
This is a feasibility study, to assess if thermal imaging and/or near infrared imaging will be useful in identifying changes in the peripheral circulation in patients with different stages of liver disease. The aim of this study is to use new and advanced thermal imaging techniques to identify changes in the peripheral circulation and hand temperature in patients with liver disease. These changes could be used as a non-invasive marker of the severity and progression of liver disease. Thermal imaging will also be used to assess the changes in the peripheral vasculature with the use of terlipressin, a drug used as treatment for specific complications of liver disease. Patients with acute or chronic liver disease from any aetiology will be recruited, along with patients without liver disease as healthy controls. Patients with disease or on drugs known to affect the peripheral vasculature will be excluded. All studies will be performed in a ward setting in the Royal Infirmary of Edinburgh. The subjects will be required for up to three sessions, each lasting 30 minutes. The session will involve static thermal images being taken, and video images of the hands warming up after being cooled for 30 seconds in water at a temperature of 7 degrees Celsius. If the patient is receiving terlipressin therapy, static images will be taken before, during and after terlipressin therapy.
Interventions
DIAGNOSTIC_TEST
Use of thermal imaging camera to capture images of peripheral vasculature (hands).
Timeline
First posted
Sep 12, 2017
Study start
Sep 1, 2019
Primary completion
Sep 1, 2019
Study completion
Dec 1, 2019
Results posted
Not reported
Registry updated
Jun 18, 2024
Outcomes
Changes in peripheral vasculature as assessed by thermal imaging
Time frame · 2 years
Changes in peripheral vasculature in response to terlipressin therapy.
Time frame · 2 years
Eligibility
Inclusion Criteria: * diagnosis of chronic liver disease (any stage) * diagnosis of acute liver disease (any aetiology) Exclusion Criteria: * on drugs known to affect peripheral circulation * conditions known to affect peripheral circulation e.g. Raynauds
Study locations
United Kingdom. Showing up to 24 locations stored in the fast local snapshot.
Univerity of Edinburgh and NHS Lothian
Edinburgh, United Kingdom
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
First Affiliated Hospital, Sun Yat-Sen University · Liver Neoplasms · Postoperative Complications
Not applicable
Completed
161
2026-07
Dayanand Medical College and Hospital · Alcoholic Hepatitis
Phase 3
Active, not recruiting
174
2026-07
Beijing Friendship Hospital · Kidney Transplant · Delayed Graft Function
Not applicable
Active, not recruiting
150
2026-07
University Hospital, Rouen · Bronchial Endoscopy
Phase 3
Completed
130
2026-06
Istanbul Medipol University Hospital · Liver Transplantation · Portal Hypertension
Not applicable
Recruiting
50
2026-04
Assistance Publique - Hôpitaux de Paris · Hemoptysis
Phase 3
Completed
315
2026-04
Noorik Biopharmaceuticals AG · Hepatorenal Syndrome · Liver Cirrhosis
Phase 2
Active, not recruiting
54
2026-04
Institute of Liver and Biliary Sciences, India · Acute-on-Chronic Liver Failure (ACLF)
Not applicable
Not yet recruiting
56
2026-03
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.